Triple-negative breast cancer trials recruiting in Texas

All Triple-negative breast cancer trials nationally

Cities in Texas

Recruiting trials in Texas

• A Beta-only IL-2 ImmunoTherapY Study
  NCT05086692 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
  NCT06022029 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, Houston
• A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
  NCT05746897 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas
• A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
  NCT05902988 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
  NCT06586957 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Dallas
• A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
  NCT06999187 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Dallas, San Antonio
• A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
  NCT05377996 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, Houston
• A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
  NCT07503808 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Fort Worth, Houston, Irving
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
  NCT06465069 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston, San Antonio
• A Study of LY4175408 in Participants With Advanced Cancer
  NCT07046923 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
  NCT06926920 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas
• A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
  NCT07115043 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston, San Antonio
• A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
  NCT07318805 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Conroe, Houston, League City, San Antonio
• Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
  NCT05983432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
  NCT06318897 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• PRE-ISPY Phase I/II Oncology Platform Program
  NCT05868226 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
  NCT06562192 · Phase: Phase 1 · Ages: 18 Years to 100 Years · Sex: All (male and female) · Texas: Houston
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
  NCT05579366 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Abilene, Austin, Dallas, Fort Worth
• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
  NCT06393374 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Abilene, Amarillo, Dallas, Flower Mound
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Abilene, Austin, El Paso, Houston
• Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
  NCT06084481 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston, San Antonio
• Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
  NCT05005403 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Houston, Irving, San Antonio
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · Texas: Austin, Bedford, Dallas, Houston
• This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
  NCT06451497 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, TX 78758, San Antonio